Condition

Spastic Paraplegia Type 4

Find a Doctor

LS
Areas of Expertise

Ludger Schols

University Of Tübingen
Male

Bio

Ludger Schols is in Tuebingen, Germany. Dr. Schols is highly experienced in treating patients with Spastic Paraplegia Type 4. They have been an author on 316 peer reviewed articles and participated in 3 clinical trials in the past 15 years. In particular, they have been an author on 16 peer reviewed articles regarding Spastic Paraplegia Type 4.

Areas of Expertise

Contact

Tuebingen, BW, DE

Latest Research

Latest Advance
Study
  • Condition: Hereditary Spastic Paraplegia Type 4 (SPG4)
  • Journal: Journal of neurology
  • Treatment Used: Regular Screening for Non-Motor Symptoms
  • Number of Patients: 118
  • Published —
This study evaluated the effectiveness of regular screening for non-motor symptoms in patients with hereditary spastic paraplegia type 4 (spasticity of the leg muscles and muscle weakness; SPG4).
Latest Advance
Study
  • Condition: Dysarthria in multisystemic ataxia
  • Journal: Journal of neurology
  • Treatment Used: Speech treatment
  • Number of Patients: 0
  • Published —
The study aimed to determine the effects of speech treatment in dysarthria in multisystemic ataxia.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Intervention Type: Diagnostic Test, Other
  • Participants: 2000
  • Start Date: October 14, 2019
Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders
Clinical Trial
  • Status: Recruiting
  • Participants: 100
  • Start Date: December 2015
Next Generation Sequencing Diagnostics - On the Road to Rapid Diagnostics for Rare Diseases
Clinical Trial
  • Status: Recruiting
  • Participants: 900
  • Start Date: May 2010
Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)

All Publications
View All

Publication
Study
  • Journal: Journal of neurology
  • Published —
PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot study.
Publication
Study
  • Journal: Stem cell research
  • Published —
Generation of the CRISPR/Cas9-mediated KIF1C knock-out human iPSC line HIHRSi003-A-1.

Contact

Tuebingen, BW, DE

Insurance

Contact them to find out if they accept your insurance plan.